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DOI 10.1016/j.chembiol.2011.01.008The Food and Drug Administration is
reviewing a first: an advanced hybrid
salmon intended for the human food
table. The fish is actually a genetically
modified (GM) Atlantic salmon made to
reach market growth in half the time of
Atlantic salmon now grown routinely in
today’s aquaculture ocean-pen farms.
The underlying technology for pro-
ducing GM Atlantic salmon was devel-
oped in 1989 when Garth Fletcher, Peter
Davies, and Choy Hew, all at Memorial
University of Newfoundland at the time,
created a gene construct for creating
transgenic Atlantic salmon. Research
papers from the team began appearingThe AquaAdvantage fish reaches the desirable nearly 9 lb weight
limit. in about 18 months compared with 30 months or more for
conventionally farmed Atlantic salmon.in journals in the early 1990s describing
the evolution of genetically modified
salmon with rapid growth curves.
Today’s commercial application is
championed by AquaBounty Technolo-
gies, based in Waltham, MA. The
company hopes to sell its AquaAdvantage
genetically modified fish eggs to ap-
proved land-based growth facilities
should the FDA provide the regulatory
go-ahead, an unknown at the time this
article went to press.
‘‘To make our fish eggs, we have in-
serted a specific heritable gene and
promoter construct into the fish eggs
that allows the salmon to grow more
rapidly than nontransgenic salmon,’’
explains Ronald Stotish, Ph.D., Aqua-
Bounty’s CEO. In effect, with a single
gene addition, the fish grow more quickly.
It does not make the fish grow to larger
sizes, just more quickly.
Expediting the Natural Life Cycle
In the first year of an Atlantic salmon’s life,
it does not grow much at all. Its growth,particularly its growth hormone, is regu-
lated by sunlight, food availability, and
water temperature because it is a cold
water fish. In its first year, the salmon
grows from an egg sac to small fry that
is a few grams. Trout, by comparison,
grow immediately and rapidly in the first
year. ‘‘We’ve allowed AquaAdvantage
salmon to grow more like a trout in its
first year of life,’’ says Stotish. The
AquaAdvantage fish reaches the desir-
able nearly 9 lb weight limit considered
prime by market standards in about
18 months compared with 30 months or
more for conventionally farmed Atlantic
salmon.Growth Hormone Gene
and Promoter Construct
The technology for making the GM
salmon is straightforward compared with
today’s complicated genomics research.
Nearly 20 years ago, Fletcher and Hew
were researching antifreeze genes that
allow some fish, such as winter flounder
and cod, to survive in cold water. They
honed in on a gene promoter, a short
DNA sequence, from the antifreeze gene
in the ocean pout fish. A promoter is
a DNA sequence that allows a gene to
be transcribed. It is a recognition site
that binds to the cells’ RNA polymerase,
allowing transcription of the growth
hormone gene to produce functional
growth hormone proteins.
The second half of the recipe includes
the growth hormone gene from the
Chinook salmon, a variety of naturally
harvested West Coast salmon. This GH
is nearly identical to that of the Atlantic
salmon—nearly 98% homologous. This
gene was chosen for practical purposes:
to see if the endogenous resident growthChemistry & Biology 18, January 28, 20hormone was being expressed in cultured
fish or the transgene. Both produce the
same functional protein, but this choice
allowed the early researchers to know
which gene was being expressed.
In the case of AquaAdvantage salmon,
the ocean pout promoter acts as a switch
that allows the growth hormone gene to
be continually transcribed consistently.
In native Atlantic salmon, the growth
hormone gene is normally only expressed
in the pituitary gland of the fish. They knew
they had to find away tomodify it so that it
would be expressed in other tissues to
avoid downregulation by the pituitary.
Because antifreeze protein genes are
expressed in liver and other tissues,
Fletcher and Hew selected the promoter
region from an ocean pout antifreeze
gene and spliced it to the coding region
of the Chinook salmon growth hormone
gene.
The gene/promoter construct is then
microinjected into developing embryos
of Atlantic salmon. Over a series of gener-
ations, they systematically scored the fish
that had incorporated the gene into their
genomic DNA and looked to see which
fish were capable of transferring it in
a heritable fashion. This proved the
construct had been incorporated into the
germ line of the fish.
Then they identified fish that were ex-
pressing the gene in a heritable fashion
and sorted through those fish to find one
that had the phenotype of choice: rapid
growth. That fish was used to establish
the line and became the founder fish of
what is now known as the AquaAdvant-
age salmon.
In native Atlantic salmon, the endoge-
nous growth hormone gene is downregu-
lated, a unique evolutionary adaptation
of the fish. It is shut off for periods of
4–5 months of the year in young salmon
at times when there is likely to be low
food, shorter days, and colder water. In
spring, when food is more abundant and
the water warms a bit, growth begins11 ª2011 Elsevier Ltd All rights reserved 1
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they do not demonstrate this sort of
downregulation, continuing to grow and
feed.
‘‘The idea is to have the fish produce
a sustained level of growth hormone
transcripts, not high levels,’’ explains
Stotish. He points out differences of the
AquaBounty salmon compared with other
transgenic salmon species. Research
from Dr. Robert Devlin of the Center for
Aquaculture and Environmental Research
at Fisheries, part of Fisheries and Oceans
Canada (DFO), an internationally known
researcher in the field of salmon aquacul-
ture and genetics, found that transgenic
salmon produced much higher levels of
growth hormone compared with non-
transgenic fish. ‘‘In contrast, in our fish,
the promoter is allowing the GH hormone
to be produced at low but sustained
levels,’’ says Stotish. ‘‘The levels of GH
are basically the same as found in a tradi-
tionally raised Atlantic salmon, but it is
enough to allow the fish to grow year-
round.’’
Single-Sex, Sterile Fish
The AquaAdvantage salmon is purposely
made to be all female, all of which are
sterile. ‘‘‘‘We did it for containment and
environmental reasons,’’ explains John
Buchanan, AquaBounty’s Director of
Research and Development. ‘‘By
breeding all female fish—which are also
sterile—they cannot breed with other
local populations in the case of escape
and create self-sustaining populations.’’
Triploidy technology is a decades-old
technology used to make the fish sterile.
It is a process that allows the fish to retain
the polar body during cell division that
allows an extra copy of the chromosomes
to be incorporated into the offspring. The2 Chemistry & Biology 18, January 28, 2011 ªcells of triploid individuals have three
sets of chromosomes. These daughter
fish, also known as 3N fish, are therefore
unable to reproduce.
‘‘We use female fish since the steriliza-
tion process we use is more effective on
the female sex,’’ adds Buchanan. Many
commercial fish species, including farm-
raised trout and tilapia, are bred with trip-
loidy technology.
The Data
The FDA is currently reviewing a variety of
safety and study data pending its decision
on allowing the AquaAdvantage salmon
to be introduced into the human food
supply. The fish are presented to the
FDA under the following description:
triploid hemizygous, all-female Atlantic
salmon (Salmo salar) bearing a single
copy of the a-form of the opAFP-GHc2
rDNA construct at the a-locus in the
EO-1a lineage.
In mid-September 2010, the FDA
Veterinary Medicine Advisory Committee
(VMAC) held a two-day meeting to discuss
theAquaAdvantagesalmon.Detailed infor-
mation can be found at the VMAC website
(http://www.fda.gov/AdvisoryCommittees/
CommitteesMeetingMaterials/Veterinary-
MedicineAdvisoryCommittee/ucm201810.
htm), including the FDA briefing packet
describing the scientific design and test
data of the GM salmon.
Aquabounty Technologies
When Fletcher and Hew created what
would become the construct for the
AquaAdvantage salmon, Aquabounty
Technologies did not exist. It evolved
from a company called A/F Protein, which
was interested in a variety of antifreeze
proteins for controlling cold-induced
damage to food medical products. When2011 Elsevier Ltd All rights reservedthey learned of Drs. Fletcher and Hew’s
discovery, the company shifted focus to
developing it as a tool for the salmon
industry.
Aquabounty claims that the fish’s
rapid growth is not its only benefit.
Contrary to farm-raised Atlantic salmon,
AquaAdvantage salmon are grown in
land-based systems. This would theoreti-
cally allow the fish to be cultivated
locally near food consumption sites,
potentially reducing the environmental
impact compared with coastal-based
farms. ‘‘By growing them efficiently in
land-based system, you regulate their
environment extremely closely,’’ says
Stotish. ‘‘This limits exposure to diseases
common in communal ocean pens and
provides another measure of security
against into wild populations.’’ It should
be noted, however, that AquaBounty’s
FDA submission only includes an applica-
tion for growing the salmon out in a facility
in Panama. To be grown in other sites,
additional approvals will need to be
sought and granted.
Today, nearly all commercial Atlantic
salmon is farm-raised in ocean pens in
various sites worldwide, notably Norway,
Chile, Scotland, and the Canadian Mari-
times. The wild Atlantic salmon fishery
has never been commercially viable.
Aquabounty has second and third
generation technologies in development
for creating sterile fish. ‘‘We have a small
zebrafish group mainly for that purpose,’’
explains Buchanan. Should the company
become viable in the long-term, they
hope to use them not only for creating
sterile salmon but perhaps other fish and
arthropod species.Alice McCarthy (glodog@comcast.net) is a science
writer based in Gloucester, Massachusetts.
